Literature DB >> 19949115

Comparison of patient-reported outcomes between hip resurfacing and total hip replacement.

E A Lingard1, K Muthumayandi, J P Holland.   

Abstract

This study compared the demographic, clinical and patient-reported outcomes after total hip replacement (THR) and Birmingham Hip Resurfacing (BHR) carried out by a single surgeon. Patients completed a questionnaire that included the WOMAC, SF-36 scores and comorbid medical conditions. Data were collected before operation and one year after. The outcome scores were adjusted for age, gender, comorbid conditions and, at one year, for the pre-operative scores. There were 214 patients with a THR and 132 with a BHR. Patients with a BHR were significantly younger (49 vs 67 years, p < 0.0001), more likely to be male (68% vs 42% of THR, p < 0.0001) and had fewer comorbid conditions (1.3 vs 2.0, p < 0.0001). Before operation there was no difference in WOMAC and SF-36 scores, except for function, in which patients awaiting THR were worse than those awaiting a BHR. At one year patients with a BHR reported significantly better WOMAC pain scores (p = 0.04) and in all SF-36 domains (p < 0.05). Patients undergoing BHR report a significantly greater improvement in general health compared with those with a THR.

Entities:  

Mesh:

Year:  2009        PMID: 19949115     DOI: 10.1302/0301-620X.91B12.22326

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  17 in total

1.  When do patient-reported assessments peak after revision knee arthroplasty?

Authors:  Ajay Malviya; Karen Bettinson; Steven M Kurtz; David J Deehan
Journal:  Clin Orthop Relat Res       Date:  2011-11-05       Impact factor: 4.176

2.  Functional outcome following aseptic single-stage revision knee arthroplasty.

Authors:  Ajay Malviya; Nigel T Brewster; Karen Bettinson; James P Holland; David J Weir; David J Deehan
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-11-22       Impact factor: 4.342

3.  Direct anterior approach for hip resurfacing: surgical technique and complications.

Authors:  Stefan Kreuzer; Kevin Leffers; Suneel Kumar
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

4.  Socio-economic impact of Birmingham hip resurfacing on patient employment after ten years.

Authors:  Ibrahim A Malek; Munawar Hashmi; James P Holland
Journal:  Int Orthop       Date:  2010-11-27       Impact factor: 3.075

5.  Do survival rate and serum ion concentrations 10 years after metal-on-metal hip resurfacing provide evidence for continued use?

Authors:  Albrecht Hartmann; Jörg Lützner; Stephan Kirschner; Wolf-Christoph Witzleb; Klaus-Peter Günther
Journal:  Clin Orthop Relat Res       Date:  2012-11       Impact factor: 4.176

6.  Patients report improvement in quality of life and satisfaction after hip resurfacing arthroplasty.

Authors:  Wael A Rahman; Nelson V Greidanus; Alexander Siegmeth; Bassam A Masri; Clive P Duncan; Donald S Garbuz
Journal:  Clin Orthop Relat Res       Date:  2013-02       Impact factor: 4.176

7.  What Are the Benefits of Hip Resurfacing in Appropriate Patients? A Retrospective, Propensity Score-Matched Analysis.

Authors:  Alexander S McLawhorn; Leonard T Buller; Jason L Blevins; Yuo Yu Lee; Edwin P Su
Journal:  HSS J       Date:  2019-12-04

8.  Mortality and implant revision rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study.

Authors:  D J W McMinn; K I E Snell; J Daniel; R B C Treacy; P B Pynsent; R D Riley
Journal:  BMJ       Date:  2012-06-14

9.  Birmingham hip resurfacing versus cementless total hip arthroplasty in patients 55 years or younger: A minimum five-year follow-up.

Authors:  Mohamad J Halawi; Sameer R Oak; David Brigati; Aretha Siggers; William Messner; Peter J Brooks
Journal:  J Clin Orthop Trauma       Date:  2017-05-23

10.  Use of porous trabecular metal augments with impaction bone grafting in management of acetabular bone loss.

Authors:  W Steven Borland; Raj Bhattacharya; James P Holland; Nigel T Brewster
Journal:  Acta Orthop       Date:  2012-08-20       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.